The contract development and manufacturing organisation, Recipharm AB (publ) announces that it has today completed the acquisition of a majority stake in Nitin Lifesciences Limited (“Nitin”), an Indian sterile injectables CMO, currently owned by the Sobti family. Recipharm has acquired 74 % of the shares for a purchase consideration of INR 6,713 million (SEK 824 million)[1] on a cash and debt free basis. Thomas Eldered, CEO of Recipharm said “I am delighted that we have now completed this transaction. The combination of Nitin and Recipharm represents an important step in the development of both companies and I am pleased that both Dr Chetan Sobti and Nitin Sobti will be continuing in their current positions”. Mr. M.M Sobti, founder of Nitin Lifesciences Ltd., commented “This partnership represents a real opportunity to take Nitin Lifesciences to a new level. The combination allows both organisations to access a wider customer base and to gain important learning from each other. The Sobti family is very pleased to be entering into this new strategic partnership which will be hugely beneficial for both companies”. Highlights · The combined entity will have enhanced scale, reach and profitability. Nitin Lifesciences had 2015 net sales of approximately INR 2 970 million (SEK 391 million) [2], corresponding to 12 % of Recipharm’s 2015 total net sales. The EBITDA margin 2015 was approximately 24 %. · Significantly bolsters presence in high growth developing territories and the deal firmly establishes Recipharm’s emerging market strategy. Provides excellent exposure and direct entry into the rapidly expanding Indian market. · Recipharm’s global position in sterile injectables including lyophilization will be further strengthened. · The implied value for 100 % of Nitin equates to INR 9,071 million (SEK 1,114 million)1and represents approximately 11.7 times 2015 EBITDA of INR 721 million (SEK 95 million)[2],[3]. · Accretive to organic growth and EPS. About Nitin Lifesciences Nitin Lifesciences Ltd is a rapidly growing Indian pharmaceutical company with a strong presence in injectable manufacturing. Established in 1994 by Mr M.M. Sobti and the late Mr M.V. Kakkar, Nitin has emerged as one of the largest small volume parenteral manufacturers in India and is engaged in contract manufacturing to major Indian and international pharmaceutical companies. Headquartered at Karnal in Northern India, Nitin has three modern facilities for small volume parenterals located at Karnal (Haryana) and at Paonta Sahib (Himachal Pradesh). The newest facility in Paonta Sahib was taken into operations in 2014 and the business provides high technology pharmaceutical manufacturing solutions. The company specializes in manufacturing liquid ampoules, liquid vials, sterile dry powder (beta lactam & non beta lactam), multidose eye/ear drops and lyophilized vials covering more than 200 formulations across various therapeutic areas including antibiotics, anti-malarial, NSAIDs, anti-inflammatory and local anesthetics. It brings a high quality customer base including a growing number of multinational Big Pharma customers supplying the Indian domestic market. The company will continue to trade as Nitin Lifesciences Ltd. In 2015 Nitin reported sales of INR 2,970 million (SEK 391 million) and an EBITDA of INR 721 million (SEK 95 million) corresponding to an EBITDA margin of 24.3 %.[4],[5] The EBITDA margin has been between 19 % and 24 % during the last three financial years and margin is expected in the lower end of this range in the coming years. Nitin is essentially debt free. Since 2012FY, Nitin has reported a CAGR of over 20 %. The current capacity will continue to allow growth but at a more moderate rate. For more information please visit www.recipharm.com or contact: Thomas Eldered, CEO, telephone: +46 8 602 52 00 Björn Westberg, CFO, ir@recipharm.com, telephone: +46 8 602 46 20 This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 7 April 2016, at 07:45 am CET. About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,700 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in France, Germany, Italy, Israel, Portugal, Spain, Sweden and the UK and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com Recipharm has retained Veritas Legal and Calissendorff Swarting as legal advisors, PwC as financial/ tax advisors and WSP as environmental advisors for the transaction. ---------------------------------------------------------------------- [1] (http://file///G:/Shared/Corporate%20Development/IR/Nile/Press%20release%20 -%20Recipharm%20completes%20acquisition%20of%20Nitin%20Lifesciences%20EN%2020150 4 11.docx#_ftnref1) Exchange rate SEK/INR 0.123 [2] (http://file///G:/Shared/Corporate%20Development/IR/Nile/Press%20release%20 -%20Recipharm%20completes%20acquisition%20of%20Nitin%20Lifesciences%20EN%2020150 4 11.docx#_ftnref2) Exchange rate SEK/INR 0.132 [3] (http://file///G:/Shared/Corporate%20Development/IR/Nile/Press%20release%20 -%20Recipharm%20completes%20acquisition%20of%20Nitin%20Lifesciences%20EN%2020150 4 11.docx#_ftnref3) Based on audited figures according to Indian GAAP [4] (http://file///G:/Shared/Corporate%20Development/IR/Nile/Press%20release%20 -%20Recipharm%20completes%20acquisition%20of%20Nitin%20Lifesciences%20EN%2020150 4 11.docx#_ftnref4) Based on audited figures according to Indian GAAP [5] (http://file///G:/Shared/Corporate%20Development/IR/Nile/Press%20release%20 -%20Recipharm%20completes%20acquisition%20of%20Nitin%20Lifesciences%20EN%2020150 4 11.docx#_ftnref5) Exchange rate SEK/INR 0.132 Recipharm AB (publ), Org. nr 556498-8425 Adress Lagervägen 7, 136 50 Jordbro, Sverige, Telefon 46 8 602 52 00, Fax 46 8 81 87 03 www.recipharm.com
Recipharm completes acquisition of a majority stake in
Top 10 Most Recent News Articles
Zensar’s AI Forum Puts Operations Before the AI Hype
Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...
Continue Reading
Lennar Lawsuit Puts Land-Light Claims Under a Microscope
Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...
Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users
Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...
Continue Reading
Yangtze Documentary Frames a Decade of Economic Change
A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...
Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline
A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...
Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer
Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...
Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets
Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...
Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions
Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...
Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf
Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...
Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk
A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...
Continue ReadingTop 5 Most Recently Viewed Articles
Eagle Pharmaceuticals Board Advances Rights Plan for Shareholders
Eagle Pharmaceuticals Board Extends Rights Plan Duration Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) has announced an update regarding its stockholder rights plan. The Board of Directors has approved an important amendment to the existing limited duration rights plan, extending its validity for one additional year, until October 30, 2026. Reason for the Amendment This...
Continue Reading
How Trump's Immigration Policies Could Impact US Growth
Trump's Immigration Policies and Economic Growth Donald Trump's approach to immigration is likely to influence the rate of migration into the United States significantly, implying a potential slowdown in the nation's economic growth. Analysts at Piper Sandler have expressed concerns that the upcoming policies could lead to a meaningful deceleration in migration rates that...
Continue Reading
Sonder Holdings Faces Nasdaq Compliance Challenges Ahead
Sonder Holdings Faces Nasdaq Compliance Challenges Sonder Holdings Inc. (NASDAQ: SOND), a cutting-edge hospitality company known for its tech-enhanced accommodations, recently received a formal notification from Nasdaq regarding a compliance issue. This is primarily due to the company's delay in filing its Q3 financial report for the period ending September 30, 2024. The...
Continue Reading
Join Us for the 2024 AvaSure Symposium Celebrating Virtual Care
Overview of the 2024 AvaSure Symposium Healthcare professionals from across the country are preparing to convene for the 2024 AvaSure Symposium. This event will focus on the significant impact of AI-driven virtual care platforms on improving patient outcomes, enhancing staff satisfaction, and ensuring a healthy return on investment (ROI). Event Information The upcoming...
Continue Reading
Revolutionizing Scientific Communication: Stempad's Winter Update
Revolutionizing Scientific Communication: Stempad's Winter Update Stempad, the world's first alternative for pen-and-paper scientific writing, has excited the academic community with the announcement of its new winter features. This innovative tool supports students, educators, and researchers in STEM fields, ensuring they have a seamless solution for effective scientific...
Continue Reading